Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation at the ESMO 2019 Congress Demonstrating Positive Results from INVICTUS Pivotal Phase 3 Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors - TC Read more about Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation at the ESMO 2019 Congress Demonstrating Positive Results from INVICTUS Pivotal Phase 3 Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors - TC
MacroGenics Presents Margetuximab Data in Gastroesophageal Cancer at the ESMO 2019 Congress - TC Read more about MacroGenics Presents Margetuximab Data in Gastroesophageal Cancer at the ESMO 2019 Congress - TC
Asian Sub-Group Analysis of Novocure’s EF-14 Phase 3 Trial of Optune® in Newly Diagnosed Glioblastoma Presented at ASNO 2019 Demonstrating Efficacy and Safety Benefits - TC Read more about Asian Sub-Group Analysis of Novocure’s EF-14 Phase 3 Trial of Optune® in Newly Diagnosed Glioblastoma Presented at ASNO 2019 Demonstrating Efficacy and Safety Benefits - TC
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer - TC Read more about Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer - TC
Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting - TC Read more about Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting - TC
Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation of Pivotal Phase 3 INVICTUS Data at the European Society for Medical Oncology (ESMO) 2019 Congress - TC Read more about Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation of Pivotal Phase 3 INVICTUS Data at the European Society for Medical Oncology (ESMO) 2019 Congress - TC
The Lancet Infectious Diseases Publishes Results from Paratek’s Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin Infections - TC Read more about The Lancet Infectious Diseases Publishes Results from Paratek’s Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin Infections - TC
Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors - TC Read more about Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors - TC
ZEJULA® (niraparib) has been nominated for the Prix Galien USA Award for Best Pharmaceutical Product - TC Read more about ZEJULA® (niraparib) has been nominated for the Prix Galien USA Award for Best Pharmaceutical Product - TC
Posters from Zai Lab, GSK/Tesaro, Macrogenics and Novocure will be presented at the ESMO Congress 2019 - TC Read more about Posters from Zai Lab, GSK/Tesaro, Macrogenics and Novocure will be presented at the ESMO Congress 2019 - TC